14 days of Premium, free.
Every scanner with live hit rates + the Market Pulse risk flag that tells you when to get defensive. No card required.
Start trial →
Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026
SION vs AARD: Which Stock Is the Better Buy Now?
Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.
As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). SION carries a Unified Composite Score of 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin), whereas AARD carries 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin).
Technical & Structure Timing Caution: SION is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on SION vs AARD. Trailing 12-month operating profitability (SION 0.0% vs AARD 0.0%) and valuation multiples (SION N/M vs AARD N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Competes within the Biotechnology value chain with $33.3M market capitalization and 0.0% operating margin.
OpEx & R&D ReinvestmentN/A
90D Engineering Disclosures0 Published
Investor FAQ SION vs AARD Key Questions & Quantitative Answers
As of Nov 16, 2026, Aardvark Therapeutics, Inc. (AARD) is the stronger overall head-to-head candidate over Sionna Therapeutics, Inc. (SION) in the Tradestie Institutional Equity Comparison Engine, winning 2–3 core matrix metrics and 2–2 across our 6-pillar institutional scorecard (led by Balance Sheet & Cash Flow, Options & Positioning). SION carries a Unified Composite Score of 45.6/100 (HOLD) at $3.12 (N/M Forward P/E, 0.0% operating margin), whereas AARD carries 57.5/100 (HOLD) at $1.26 (N/M Forward P/E, 0.0% operating margin). Technical & Structure Timing Caution: SION is currently in a short-term Weinstein Markdown pullback below its falling 50-day moving average and Breakdown options structure phase (RSI 31.9); meanwhile AARD is in a short-term Weinstein Markdown pullback below its falling 50-day moving average (RSI 30.7). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.
SION leads the Growth & Scale pillar: SION posts +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin), compared with AARD at +0.0% YoY revenue growth and +0.0% YoY earnings growth on N/A TTM revenue (N/A gross margin, 0.0% operating margin). On trailing 12-month operating scale, SION generates N/A in USD-normalized revenue versus N/A for AARD. In operating R&D and SG&A reinvestment, SION deploys N/A (0 90-day corporate R&D disclosures) versus N/A (0 disclosures) for AARD.
SION and AARD trade at balanced relative valuation multiples. SION trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin), whereas AARD trades at N/M Forward P/E, N/M Trailing P/E, N/M PEG, and N/M EV/Revenue (unreported FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against SION (-39.0% ROE) versus AARD (-66.0% ROE) capital efficiency.
In options market volatility and institutional positioning, SION carries 87.7% implied volatility (10th %ile, Compressed (<25th %ile)), a 93.27x (Put-Skewed) Put/Call open-interest ratio, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.97β · 78% Vol realized risk). By comparison, AARD carries 147.3% implied volatility (26th %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (4.10β · 288% Vol realized risk).
Cross-Compare 1-Click Peer Rivalries & Single-Stock Research
Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.